Future studies could evaluate the pathophysiologic differences in these distinct phenotypes by assessing inflammatory cytokine profiles in MIS-C patients across the COVID-19 waves and in patients with high versus low NT-proBNP levels. This evidence concerns the gene NPPB and COVID-19.